STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
Ed Silverman·
·1 min read
·
0 reactions
·
0 comments
·
5 views
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
Original article
STAT · Ed Silverman
Anonymous · no account needed
Discussion
0 commentsMore from STAT
Dexcom RCT suggests CGM benefits for broad diabetes population
STAT·7
STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored
STAT·7
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
STAT·9
STAT+: Novo underwhelmed by drug it once fought Pfizer for
STAT·14
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
STAT·12
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT·17